Efficacy of chronic statin therapy on major cardiac events after coronary artery bypass grafting: Low-dose versus high-dose

Medicinski Glasnik

Volumn 12, Issue 2, 2015, Pages 196-201

  Kunt, Ayşegül ^a   Özcan, Sedat ^b   Küçüker, Aslihan ^c   Odabaşi, Dolunay ^a   Kunt, Alper Sami ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Chronic statin treatment; Coronary bypass grafting; Major cardiac events

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; TROPONIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY OCCLUSION; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INTERNAL MAMMARY ARTERY; KAPLAN MEIER METHOD; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; REVASCULARIZATION; SAPHENOUS VEIN; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84954504749     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: 10.17392/795-15     Document Type: Article

References (23)

1. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110:674-8.
2. Patti G, Pasceri V, Colonna G, Miglionico M, Fis- chetti D, Sardella G, Atorvastatin pretreatment improves outcomes in patients with acute coronaryan. syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49:1272-8.
3. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of peri-procedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099-106.
4. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28:616-26.
5. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97:916-31.
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Cholesterol Treatment Tri- alists’ (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective metaanalysis of data from 90.056 participants in 14 randomized trials of statins. Lancet 2005; 366:1267-78.
7. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fon- ger J, Gardner TJ. ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 34:1262-347.
8. Reiber JHC, van der Zwet PMJ, von Land CD. Quantitative coronary angiography: equipment and technical requirements. In: Reiber JHC, Serruys PW (Eds.). Advances in Quantitative Coronary Arteriography. Vol. 137 of Developments in Cardiovascular Medicine. Dordrecht, Netherlands: Kluwer Academic Publishers; 1993:75-111.
9. Canner PL, Thompson B, Knatterud GL, Geller N, Campeau L, Zucker D. An application of the Zucker- Wittes modified ratio estimate statistic in the POST CABG Clinical Trial. Control Clin Trials 1997; 18:318-27.
10. Campeau L, Knatterud GL, White C and the POST CABG Clinical Trial Investigators. The NHLBI PostCoronary Artery Bypass Graft Clinical Trial (POST CABG) angiographic outcomes. In: Bruschke AVG, Reiber JHC, Lie KI (Eds.) Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis. Vol. 180. London, UK: Kluwer Academic Publishers; 1996:203-213.
11. Sacks FM, Pfeifer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-9.
12. Anonymus. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-57.
13. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Preprocedural statin medication reduces the extent of periprocedural non- Q-wave myocardial infarction. Circulation 2002; 106:2180-3.
14. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliter- no DJ, Topol EJ, Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-6.
15. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moli- terno DJ, Topol EJ, Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107:1750-6.
16. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011; 123:1622-32.
17. Carrier M, Cossette M, Pellerin M, Hebert Y, Bouchard D, Cartier R, Statin treatment equalizes longterm survival between patients with single and bilateral internal thoracic artery grafts. Ann Thorac Surg 2009; 88:789-95.
18. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113:2363-72.
19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
20. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-39.
21. Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311:1329-32.
22. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28:616-26.
23. Cashin-Hemphill L, Mack WJ, Pogoda JM, San- marco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipolniacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264:3013-7.